In our study, the CQ and 3-MA treatment significantly enhanced the sensitivity of the cervical cancer and HCC cells to cisplatin in vivo and in vitro and partially relieved the BCAT1-induced resistance to cisplatin. This evidence concerns the gene BCAT1 and cervical cancer.